Extended Data Fig. 8: Additional data on the analysis of PCSK9, H2-K1 and LDLR in murine tumour cells.
From: Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
a, Lentivirus-mediated overexpression of HA-tagged H2-K1 in B16F10 cells as determined by western blot analysis. The analysis was done once. b, c, Tumour-growth delay (b) and Kaplan–Meier survival curve (c) of tumour-bearing C57BL/6 mice implanted with vector control or H2-K1-overexpressing B16F10 cells. Error bars show means ± s.e.m.; n = 5 tumours in each group; P-values were determined by two-way ANOVA (b) and log-rank test (c). d, e, Tumour-growth delay (d) and Kaplan–Meier survival curves (e) in mice injected with vector control, H2-K1-knockdown, PCSK9-knockout, or PCSK9-knockout plus H2-K1-knockdown B16F10 cells. n = 5 mice per group. Error bars show means ± s.e.m.; P-values were determined by two-way ANOVA (d) and log-rank test (e). f, Western blot analysis of LDLR knockdown in control and PCSK9KO B16F10 tumour cells. The analysis was done once. g, h, Tumour-growth delay (g) and Kaplan–Meier survival curves (h) from LDLR KD and LDLR KD/PCSK9KO B16F10 tumours. n = 5 mice per group. Error bars show means ± s.e.m.; P values were determined by two-way ANOVA (h) and log-rank test (i). i, Flow-cytometric analysis of MHC I expression in tumours formed from tdTomato-labelled control and LDLRKD B16F10 cells. n = 6 biologically independent tumours. Error bars show means ± s.e.m.; P-values were calculated by unpaired two-sided t-test. j, Flow-cytometric analysis of MHC I expression in tumours formed from tdTomato-labelled LDLR KD (n = 6) and LDLR KD/PCSK9KO cells (n = 4). Error bars show means ± s.e.m.; P-values were calculated by unpaired two-sided t-test.
